PODD — INSULET CORP

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1145197 ·
Last close
$159.61
Market Cap
$11.06B
52W High
$241.90
52W Low
$140.63
ADV30
1,804,440
Next earnings
2026-08-06
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 761,700,000 529,100,000 122,200,000 91,100,000 2,987,200,000 480,400,000 1,684,600,000
Dec 2025 783,800,000 568,600,000 146,300,000 101,600,000 3,190,400,000 716,100,000 1,675,100,000
Sep 2025 706,300,000 510,100,000 117,700,000 87,600,000 3,029,300,000 757,500,000 1,645,000,000
Jun 2025 649,100,000 452,200,000 121,100,000 22,500,000 3,469,200,000 1,121,500,000 2,006,900,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$619,200,000
Investing CF
$-234,700,000
Financing CF
$-1,192,800,000
CapEx
$-231,500,000
Dividends Paid
Buybacks
$-359,600,000
EPS Diluted TTM
$4.30
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$378,500,000
Inventory
$462,500,000
Receivables
$544,600,000
ST Investments
EBIT TTM
$469,200,000
Pretax Income TTM
$404,400,000
Interest Exp TTM
$64,800,000
Analysts
23

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,900,800,000
EBITDA
$602,000,000
Free Cash Flow
$253,375,008
Enterprise Value
$11,027,891,200
Total Cash
$480,400,000
Total Debt
$1,014,000,000
Shares Out
69,264,674
Trailing EPS
$4.27
Book Value
$18.81
ROE
23.0%
ROA
9.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,708,100,000 473,800,000 247,100,000 3,190,400,000 1,675,100,000 569,300,000
Dec 2024 2,071,600,000 308,900,000 418,300,000 3,087,700,000 1,876,100,000 430,200,000
Dec 2023 1,697,100,000 220,100,000 206,300,000 2,588,200,000 1,855,500,000 145,700,000
Dec 2022 1,305,300,000 37,600,000 4,600,000 2,251,100,000 1,774,700,000 119,000,000

TTM Snapshot

Revenues TTM
$1,593,000,000
NetIncome TTM
$136,800,000
OpCashFlow TTM
$0
Assets (Latest)
$3,087,700,000
Forward EPS
$8.09

Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $200.00 · spot: $159.61 · call volume: 208 · put volume: 1,310
Expected Move to 2026-06-18: ±$9.54 (5.98%) — implied range $150.07$169.15 · ATM straddle on $160.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BAX BAXTER INTERNATIONAL INC $10.34B $20.03
PEN Penumbra Inc $12.63B $321.06
ALGN ALIGN TECHNOLOGY INC $12.76B $178.10
SNNUF SMITH & NEPHEW PLC $12.82B $15.10
MASI MASIMO CORP $9.42B $179.95

News headlines (Yahoo Finance, 1h cache)

Insulet (PODD) Enhances Omnipod 5 System with New Target Glucose Option
2026-06-08 03:44 · Yahoo
Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care
2026-06-06 11:00 · Yahoo
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?
2026-06-05 15:30 · Yahoo
Dexcom buys Nutrisense; Insulet rolls out patch pump update
2026-06-05 10:25 · Yahoo
Is Omnipod 5’s Algorithm and Libre 3 Plus Upgrade Altering The Investment Case For Insulet (PODD)?
2026-06-05 08:15 · Yahoo
3 Reasons We’re Fans of Insulet (PODD)
2026-06-04 16:45 · Yahoo
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
2026-06-04 16:10 · Yahoo
Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessi
2026-06-04 11:00 · Yahoo
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
2026-06-03 15:25 · Yahoo
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor
2026-06-03 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.